Shanghai RAAS reports semi-annual results, board approves actions

Shanghai RAAS Blood Products Co., Ltd. announced its unaudited 2025 semi-annual financial report, showing operating income of 3,952,191,668.60 yuan and net profit attributable to shareholders of 1,029,892,162.06 yuan. The board of directors held its 13th meeting on August 28, 2025, approving the full text and summary of the 2025 semi-annual report. The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital.

A separate filing details funds occupied by related parties and other related party transactions. For the first half of 2025, funds occupied by related parties amounted to 0 yuan, and total related party transactions were 50,710.73 yuan. The board and supervisory board confirm all information disclosed is true, accurate, and complete.

The company also disclosed its 2025 semi-annual financial report summary, which includes key financial data and operational highlights from January 1 to June 30, 2025. The full report is available on cninfo.com.cn, with the summary published in major securities newspapers.